Dr Goli Samimi
Group Leader, Ovarian Cancer, Cancer Research Program, Garvan Institute of Medical Research; Conjoint Senior Lecturer, Faculty of Medicine, The University of New South Wales
Email: g.samimi 'at' garvan.org.au
Research Group: Ovarian Cancer
As Leader of the Ovarian Cancer Group, our research focus involves identification of methylation profiles in plasma DNA that have potential as diagnostic markers for early stage ovarian cancer.
Education
2006 MPH, Harvard School of Public Health, Boston, MA (USA)
2004 PhD, University of California, San Diego, La Jolla, CA (USA)
1997 BS, University of California, Los Angeles, Los Angeles, CA (USA)
Awards and Honours
2008 Fellows Award for Research Excellence, National Institutes of Health, Bethesda, MD (USA)
2008 Merit Award, Cancer Prevention Fellowship Program, NCI, Bethesda, MD (USA)
2008 Best Basic Science Poster Presentation, Society of Gynecological Oncologists 39th Annual Meeting on Women’s Cancer (USA)
2007 Fellows Award for Research Excellence, National Institutes of Health, Bethesda, MD (USA)
2003 AACR-AFLAC Scholar-in-Training Award, American Association for Cancer Research (USA)
2002 AACR Travel Award, Rebecca and John Moores UCSD Cancer Center (USA)
2001 AACR-BD Pharmingen Scholar-in-Training Award, American Association for Cancer Research(USA)
1997 Graduated Cum Laude, University of California, Los Angeles (USA)
Selected Publications
Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16(6):521-532, 2009.
Samimi G, Ozbun L, Johnson ME, Mok SC and Birrer MJ. Biomarkers of mucinous tumors of the ovary. Disease Markers 23(5-6):389-396, 2007.
Samimi G, Kishimoto S, Manorek G, Breaux JK and Howell SB. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM-118 the major metabolite of satraplatin. Cancer Chemother Pharmacol 59(3):301-312, 2007.
Samimi G and Howell SB. Modulation of the cellular pharmacology of JM-118, the major metabolite of satraplatin, by copper influx and efflux transporters. Cancer Chemother Pharmacol 57(6):781-788, 2006.
Samimi G, Manorek G, Castel R, Breaux JK, Cheng TC, Berry CC, Los G and Howell SB. cDNA microarray-based identification of genes and mechanisms associated with oxaliplatin resistance. Cancer Chemother and Pharmacol 55(1):1-11, 2005.
Samimi G, Katano K, Holzer AK, Rochdi M, Tomioka M, Goodman M, Safaei R and Howell SB. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10(14):4661-4669, 2004. Cover Article.
Samimi G, Katano K, Holzer AK, Safaei R and Howell SB. Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol Pharmacol 66(1):25-32, 2004.
Samimi G, Varki NM, Wilczynski S, Safaei R, Alberts DS and Howell SB. Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin Cancer Res 9(16 pt 1):5853-5859, 2003. Cover Article.
Accompanying Editorial: Kruh GD. Lustrous insights into cisplatin accumulation: copper transporters. Clin Cancer Res 9(16 pt 1):5807-5809, 2003.
Mishima M*, Samimi G*, Kondo A, Lin X and Howell SB. The cellular pharmacology of oxaliplatin resistance. Eur J of Cancer 38(10):1405-1412, 2002.
Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS and Howell SB. Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 6(4):1415-1421, 2000.
Search for all publications by G Samimi
